Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
182
-
Total 13F shares, excl. options
-
66,978,934
-
Shares change
-
-977,105
-
Total reported value, excl. options
-
$2,733,829,933
-
Value change
-
-$33,681,490
-
Put/Call ratio
-
28%
-
Number of buys
-
88
-
Number of sells
-
-78
-
Price
-
$40.82
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2021
214 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q2 2021.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 182 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66,978,934 shares
of 107,800,271 outstanding shares and own 62.13% of the company stock.
Largest 10 shareholders include FMR LLC (12,122,894 shares), VANGUARD GROUP INC (6,828,437 shares), WASATCH ADVISORS INC (6,506,789 shares), BlackRock Inc. (5,718,849 shares), Bellevue Group AG (3,609,919 shares), MARSHALL WACE, LLP (2,771,304 shares), LORD, ABBETT & CO. LLC (2,145,588 shares), CITADEL ADVISORS LLC (1,561,392 shares), STATE STREET CORP (1,500,029 shares), and FRANKLIN RESOURCES INC (1,364,652 shares).
This table shows the top 182 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.